Direct detection of mutations in the breast and ovarian cancer susceptibility gene BRCA1 by PCR-mediated site-directed mutagenesis

Elizabeth M. Rohlfs, William G. Learning, Kenneth J. Friedman, Fergus J Couch, Barbara L. Weber, Lawrence M. Silverman

Research output: Contribution to journalArticle

60 Citations (Scopus)

Abstract

The tumor suppressor genes BRCA1 and BRCA2, which confer increased susceptibility to breast and (or) ovarian cancer, were recently identified. Mutation analysis of BRCA1 has demonstrated significant allelic heterogeneity; however, some distinct mutations have been detected in unrelated individuals. The most notable is the 185delAG mutation, which occurs at an estimated frequency of ~1% in individuals of Ashkenazi Jewish descent [1]. Although consensus has not been reached regarding clinical testing for mutations in BRCA1, a tiered strategy may be appropriate, in which direct testing for the more common mutations is one component. Specific alleles can be detected by using PCR-mediated site-directed mutagenesis (PSM), which alters the PCR products derived from either the wild-type or mutant allele to create or destroy a restriction endonuclease recognition site. Recognition sites are introduced by a base substitution in one of the primers. The alleles are then resolved by electrophoresis of the digested PCR products. We have applied this technique to the detection of four BRCA1 mutations: 185delAG, 5382insC, E1250X, and R1443X. Another mutation, 1294del40, can be resolved from the wild-type allele by high-resolution gel electrophoresis alone. The PSM technique is sensitive, does not require radioactivity, and is specific for individual mutations.

Original languageEnglish (US)
Pages (from-to)24-29
Number of pages6
JournalClinical Chemistry
Volume43
Issue number1
StatePublished - 1997
Externally publishedYes

Fingerprint

Mutagenesis
Neoplasm Genes
Site-Directed Mutagenesis
Electrophoresis
Ovarian Neoplasms
Genes
Breast Neoplasms
Polymerase Chain Reaction
Mutation
DNA Restriction Enzymes
Radioactivity
Testing
Tumors
Substitution reactions
Gels
Alleles
Tumor Suppressor Genes
Breast

Keywords

  • genetics
  • ovarian cancer
  • polymerase chain reaction

ASJC Scopus subject areas

  • Clinical Biochemistry

Cite this

Rohlfs, E. M., Learning, W. G., Friedman, K. J., Couch, F. J., Weber, B. L., & Silverman, L. M. (1997). Direct detection of mutations in the breast and ovarian cancer susceptibility gene BRCA1 by PCR-mediated site-directed mutagenesis. Clinical Chemistry, 43(1), 24-29.

Direct detection of mutations in the breast and ovarian cancer susceptibility gene BRCA1 by PCR-mediated site-directed mutagenesis. / Rohlfs, Elizabeth M.; Learning, William G.; Friedman, Kenneth J.; Couch, Fergus J; Weber, Barbara L.; Silverman, Lawrence M.

In: Clinical Chemistry, Vol. 43, No. 1, 1997, p. 24-29.

Research output: Contribution to journalArticle

Rohlfs, Elizabeth M. ; Learning, William G. ; Friedman, Kenneth J. ; Couch, Fergus J ; Weber, Barbara L. ; Silverman, Lawrence M. / Direct detection of mutations in the breast and ovarian cancer susceptibility gene BRCA1 by PCR-mediated site-directed mutagenesis. In: Clinical Chemistry. 1997 ; Vol. 43, No. 1. pp. 24-29.
@article{c41341706d454b3a96f8a9701dfa2216,
title = "Direct detection of mutations in the breast and ovarian cancer susceptibility gene BRCA1 by PCR-mediated site-directed mutagenesis",
abstract = "The tumor suppressor genes BRCA1 and BRCA2, which confer increased susceptibility to breast and (or) ovarian cancer, were recently identified. Mutation analysis of BRCA1 has demonstrated significant allelic heterogeneity; however, some distinct mutations have been detected in unrelated individuals. The most notable is the 185delAG mutation, which occurs at an estimated frequency of ~1{\%} in individuals of Ashkenazi Jewish descent [1]. Although consensus has not been reached regarding clinical testing for mutations in BRCA1, a tiered strategy may be appropriate, in which direct testing for the more common mutations is one component. Specific alleles can be detected by using PCR-mediated site-directed mutagenesis (PSM), which alters the PCR products derived from either the wild-type or mutant allele to create or destroy a restriction endonuclease recognition site. Recognition sites are introduced by a base substitution in one of the primers. The alleles are then resolved by electrophoresis of the digested PCR products. We have applied this technique to the detection of four BRCA1 mutations: 185delAG, 5382insC, E1250X, and R1443X. Another mutation, 1294del40, can be resolved from the wild-type allele by high-resolution gel electrophoresis alone. The PSM technique is sensitive, does not require radioactivity, and is specific for individual mutations.",
keywords = "genetics, ovarian cancer, polymerase chain reaction",
author = "Rohlfs, {Elizabeth M.} and Learning, {William G.} and Friedman, {Kenneth J.} and Couch, {Fergus J} and Weber, {Barbara L.} and Silverman, {Lawrence M.}",
year = "1997",
language = "English (US)",
volume = "43",
pages = "24--29",
journal = "Clinical Chemistry",
issn = "0009-9147",
publisher = "American Association for Clinical Chemistry Inc.",
number = "1",

}

TY - JOUR

T1 - Direct detection of mutations in the breast and ovarian cancer susceptibility gene BRCA1 by PCR-mediated site-directed mutagenesis

AU - Rohlfs, Elizabeth M.

AU - Learning, William G.

AU - Friedman, Kenneth J.

AU - Couch, Fergus J

AU - Weber, Barbara L.

AU - Silverman, Lawrence M.

PY - 1997

Y1 - 1997

N2 - The tumor suppressor genes BRCA1 and BRCA2, which confer increased susceptibility to breast and (or) ovarian cancer, were recently identified. Mutation analysis of BRCA1 has demonstrated significant allelic heterogeneity; however, some distinct mutations have been detected in unrelated individuals. The most notable is the 185delAG mutation, which occurs at an estimated frequency of ~1% in individuals of Ashkenazi Jewish descent [1]. Although consensus has not been reached regarding clinical testing for mutations in BRCA1, a tiered strategy may be appropriate, in which direct testing for the more common mutations is one component. Specific alleles can be detected by using PCR-mediated site-directed mutagenesis (PSM), which alters the PCR products derived from either the wild-type or mutant allele to create or destroy a restriction endonuclease recognition site. Recognition sites are introduced by a base substitution in one of the primers. The alleles are then resolved by electrophoresis of the digested PCR products. We have applied this technique to the detection of four BRCA1 mutations: 185delAG, 5382insC, E1250X, and R1443X. Another mutation, 1294del40, can be resolved from the wild-type allele by high-resolution gel electrophoresis alone. The PSM technique is sensitive, does not require radioactivity, and is specific for individual mutations.

AB - The tumor suppressor genes BRCA1 and BRCA2, which confer increased susceptibility to breast and (or) ovarian cancer, were recently identified. Mutation analysis of BRCA1 has demonstrated significant allelic heterogeneity; however, some distinct mutations have been detected in unrelated individuals. The most notable is the 185delAG mutation, which occurs at an estimated frequency of ~1% in individuals of Ashkenazi Jewish descent [1]. Although consensus has not been reached regarding clinical testing for mutations in BRCA1, a tiered strategy may be appropriate, in which direct testing for the more common mutations is one component. Specific alleles can be detected by using PCR-mediated site-directed mutagenesis (PSM), which alters the PCR products derived from either the wild-type or mutant allele to create or destroy a restriction endonuclease recognition site. Recognition sites are introduced by a base substitution in one of the primers. The alleles are then resolved by electrophoresis of the digested PCR products. We have applied this technique to the detection of four BRCA1 mutations: 185delAG, 5382insC, E1250X, and R1443X. Another mutation, 1294del40, can be resolved from the wild-type allele by high-resolution gel electrophoresis alone. The PSM technique is sensitive, does not require radioactivity, and is specific for individual mutations.

KW - genetics

KW - ovarian cancer

KW - polymerase chain reaction

UR - http://www.scopus.com/inward/record.url?scp=0031012211&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031012211&partnerID=8YFLogxK

M3 - Article

C2 - 8990217

AN - SCOPUS:0031012211

VL - 43

SP - 24

EP - 29

JO - Clinical Chemistry

JF - Clinical Chemistry

SN - 0009-9147

IS - 1

ER -